P Baur

Universität Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany

Are you P Baur?

Claim your profile

Publications (3)2.87 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The hepatitis C-virus (HCV) is the main etiologic agent of posttransfusion hepatitis (PTH). Most patients depending on hemodialysis need transfusion of blood before kidney transplantation. Of 272 patients after kidney transplantation, 27 (10%) were found to be anti-HCV-ELISA-positive (HCV-Antibody-ELISA, Ortho Diagnostics). The antibodies could be neutralized by HCV C-100-3 antigen. Eight of 22 patients (36%) who had more than one kidney transplantation were classified anti-HCV positive [30% (8/27) of all anti-HCV positive patients]. The number of transfused blood units ranged from 0 to 99 BU. Receiving more than one kidney graft or the transfusion of more than 5 units of blood increased the risk for HCV infection 3.5 or 4.1 times, respectively, compared with one transplantation or less than 5 units of blood. No significant interactions were seen between these two variables. Of the anti-HCV positive patients, 48% were anti-HBc negative as well as HBs-antigen negative, 52% were anti-HBc positive.
    Annals of Hematology 02/1991; 62(2-3):68-73. · 2.87 Impact Factor
  • P Baur, D Roelcke
    [Show abstract] [Hide abstract]
    ABSTRACT: Since 1986 only anti-HBc negative blood donors had been admitted for blood donations at the Heidelberg University Blood Bank. The maximum ALT-level for blood donors was set at less than or equal to 30 U/l. Four of 1514 blood donors (0.26%) were found to be anti-HCV positive. The routine screening of blood donors for anti-HBc in combination with an ALT-level less than or equal to 30 U/l leads to the observed lower prevalence compared to the rate found in German blood donors (0.26%/0.42% [1]).
    Beiträge zur Infusionstherapie = Contributions to infusion therapy 02/1991; 28:25-6.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of anti-HCV in patients after kidney transplantation was tested by HCV-Antibody-ELISA (Ortho Diagnostics). In addition, reactive samples were tested by HCV-EIA (Abbott Laboratories), neutralization, anti-HBc (Corzyme, Abbott) and by HBs-Ag (Auszyme, Abbott). 27 of 271 patients (10%) were anti-HCV positive. Receiving more than one kidney graft (TPL) or the transfusion of more than four blood units (BU) increases the risk of HCV infection four times (OR: 4.1; p less than 0.01) or 2.5 times (OR: 2.5; p less than 0.05), respectively, compared with one TPL or less than 4 BU. Receiving more than one kidney graft and transfusion of more than four BU raises the risk of HCV infection 6.8 times. 52% of anti-HCV positive patients were anti-HBc positive, 48% were anti-HBc negative as well as HBs-Ag negative.
    Beiträge zur Infusionstherapie = Contributions to infusion therapy 02/1991; 28:27-8.